Activist Broadwood Partners Secures Board Seats, CEO Departure at STAAR Surgical

summarizeSummary

Activist investor Broadwood Partners, holding a 31.1% stake, has reached a cooperation agreement with STAAR Surgical Co., leading to the appointment of three new directors, including two from Broadwood, and the impending departure of the current CEO.

check_boxKey Events

• Cooperation Agreement Reached

  Broadwood Partners and STAAR Surgical Co. entered into a cooperation agreement on January 14, 2026, resolving a proxy contest.

• Significant Board Changes

  The Board size increased to seven, with Neal C. Bradsher (Broadwood), Richard T. LeBuhn (Broadwood), and Christopher Min Fang Wang (Yunqi Capital) appointed as new directors.

• CEO Departure

  Stephen C. Farrell resigned from the Board and is expected to step down as CEO by January 31, 2026.

• Activist Influence

  Broadwood Partners, holding a 31.1% stake, has gained substantial influence over the company's governance and strategic direction.

auto_awesomeAnalysis

This Schedule 13D/A filing details a significant governance overhaul at STAAR Surgical Co. following a successful activist campaign by Broadwood Partners. The cooperation agreement results in the immediate resignation of the current CEO from the board and his full departure from the CEO role by January 31, 2026. Broadwood, a 31.1% owner, has secured two board seats for its representatives, Neal C. Bradsher and Richard T. LeBuhn, alongside Christopher Min Fang Wang from Yunqi Capital, another substantial shareholder. This represents a major shift in the company's leadership and strategic direction, with the activist investor gaining significant influence. The company also agreed to reimburse Broadwood up to $6 million in expenses, underscoring the scale of the activist's efforts. Broadwood's recent open market purchases of approximately 1.93 million shares further demonstrate their strong conviction in the company's future under the new governance structure.